Contrast-induced nephropathy in outpatients with preexisting renal impairment: a comparison between intravenous iohexol and iodixanol

Concern for contrast-induced nephropathy (CIN) may result in administration of more costly agents. We prospectively compared outpatient CIN incidence of iodixanol to iohexol. Patients were randomized to receive 100ml of iohexol (n=47) or iodixanol (n=55). We compared patients who developed CIN using...

Full description

Saved in:
Bibliographic Details
Published in:Clinical imaging 2016-09, Vol.40 (5), p.902-906
Main Authors: Cernigliaro, Joseph G., Haley, William E., Adolphson, Doug P., Jepperson, Maria A., Crook, Julia E., Thomas, Colleen S., Parker, Alexander S.
Format: Article
Language:English
Subjects:
Acute Kidney Injury - chemically induced
Acute Kidney Injury - diagnosis
Acute Kidney Injury - epidemiology
Adult
Age
Aged
Aged, 80 and over
Body mass index
Confidence intervals
Contrast agents
Contrast Media - administration & dosage
Contrast Media - adverse effects
Contrast nephropathy (CIN)
Diabetes
Dose-Response Relationship, Drug
Female
Florida - epidemiology
Humans
Imaging
Impairment
Incidence
Injections, Intravenous
Intervals
Iodixanol
Iohexol
Iohexol - administration & dosage
Iohexol - adverse effects
Liver diseases
Male
Mathematical analysis
Middle Aged
Multiple myeloma
Outpatient
Outpatients
Patients
Prognosis
Receiving
Renal Insufficiency - complications
Renal Insufficiency - diagnosis
Renal Insufficiency - epidemiology
Tomography, X-Ray Computed - adverse effects
Tomography, X-Ray Computed - methods
Triiodobenzoic Acids - administration & dosage
Triiodobenzoic Acids - adverse effects
White people
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Concern for contrast-induced nephropathy (CIN) may result in administration of more costly agents. We prospectively compared outpatient CIN incidence of iodixanol to iohexol. Patients were randomized to receive 100ml of iohexol (n=47) or iodixanol (n=55). We compared patients who developed CIN using the Wilson score interval and also calculated an odds ratio for the development of CIN. CIN rate for iohexol was 2% compared to 9% for iodixanol. Those receiving iodixanol were almost 5 times more likely to experience CIN. These results do not suggest a benefit of iodixanol over iohexol in the study population.
ISSN:0899-7071
1873-4499
DOI:10.1016/j.clinimag.2016.04.008